Parkwalk Investing in Innovation

Opportunities EIS Fund

An early stage investment fund providing tax benefits under the **Enterprise Investment Scheme**



active investor in university spin-outs

10+ year track

record

returned in cash to Parkwalk investors to date

EIS Fund at a glance:

Sector:

Knowledge Intensive university spin-outs

Investment stage:

Series A-C

Portfolio size:

8 individual companies

Close date:

Evergreen

Target deployment:

12-18 months from initial subscription

Min investment:

£25,000

Do not invest unless you are prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.

Please refer to the Risk Summary document for further information.



Key Risks:


EIS investments involve a high degree of risk and are not suitable for all investors. Please see the risk warnings section in this summary, they must be read in conjunction with the Fund Information Memorandum. Investors could lose part or all of their capital invested.

Investment Strategy


4 out of 10 top rated universities in the world are British

QS World Rankings 2022

- Founded in 2009, Parkwalk invest in world-class university spinouts in 'hard science' and deep-tech, commercialising scientific discoveries backed by intellectual property
- We have unique deal flow in this sector, including managing early-stage funds in partnership with the Tech Transfer Offices of the universities of Cambridge, Oxford, Bristol and Imperial College
- We aim to co-invest alongside institutional investors on each deal
- We give each investor a diverse portfolio of 8 investments across the maturity spread (early to later stage investments) and differing technology sectors



Data as at April 2023



Data as at April 2023

Investment **Examples**

We back innovative IP-rich university spin-outs across DeepTech and Hard Science sectors, and investment stages A-C. By investing in Parkwalk, you are buying into some of the brightest prospects for Britain's future economy.



Charco Neurotech

Wearable device to manage Parkinson's symptoms

University: Imperial College

Last Investment Round: \$10m, Series A

Co-investors:









Cambridge GaN Devices

Gallium Nitride (GaN) power devices

University: Cambridge

Last Investment Round: \$9.5m, Series A

Co-investors:







Good
Health and
Well-being



Industry,
Innovation
and
Infrastructure



Parkwalk Impact & ESG

We believe the distinct asset class of university spinouts has the ability not only to generate attractive investment returns but also positive returns for broader society. Much of our portfolio is aligned with the 17 UN Sustainable Development Goals (SDGs).



Bramble

Low-cost hydrogen fuel cell

University: UCL

Last Investment Round: £35m, Series B

Co-investors:









Oxbotica

Autonomous driving software

University: Oxford

Last Investment Round: \$60m, Series B

Co-investors:



Tencent 腾讯



Affordable and clean energy



Sustainable
Cities and
Communities



How to invest

After reading the Information Memorandum and you have consulted your financial adviser, please complete the relevant Application Form and return either:



Scanned copy to investor.relations@parkwalkadvisors.com



By Post to: Apex, Mainspring Nominees Ltd, 6th Floor, 125 London Wall, London, EC2Y 5AS

If you have any questions regarding applications please contact the Parkwalk team on 020 7759 2285.

Fees

Parkwalk's fee structure is competitive. In addition, Parkwalk generally avoids charging monitoring or other hidden fees to portfolio companies.

Initial Fee	3%
Annual Management Fee	1.5% (paid in cash for 2.5 years then accrued) VAT applicable
Performance Incentive Fee	20% only after investors have received back £1 per £1 invested, net of adviser fees. Performance fee payable on a portfolio basis.
Third Party Custodian Fees	0.20% dealing charge, 0.25% admin charge, taken for 5 years
Total % available for tax relief	Target of 91% of initial subscription (excluding any adviser fees)



If you would like to discuss the fund please contact our sales team on sales@parkwalkadvisors.com or 020 7759 2285







WINNER BEST EIS INVESTMENT MANAGER

WINNER MOST IMPACTFUL INVESTMENT WINNER
BEST NEW
PRODUCT
OR SERVICE

2019
WINNER
EXIT
OF THE
YEAR
OF THE YEAR

Risk Warning:

This financial promotion was approved on 14/09/2023 and is issued by Parkwalk Advisors Limited ("Parkwalk") which is authorised and regulated by the Financial Conduct Authority with firm reference number 502237. Investments referred to in this publication are not suitable for all investors.

Interested parties are strongly recommended to seek specialist financial and tax advice before investing in any product. Capital is at risk and investors may not get back the full amount invested. Tax treatment depends on the individual circumstances of each investor and may be subject to change.

Past performance is not a reliable indicator of future results, and the value of investments may go down as well as up. Projections and forecasts are also not a reliable indicator of future performance. Investments in small and unquoted companies carry a higher risk than many other forms of investment. Any investment in a Parkwalk product must only be made on the basis of the terms of the full Information Memorandum.

Parkwalk is not able to provide advice as to the suitability of investing in any product.

Registered address: 3 Pancras Square, King's Cross, London N1C 4AG